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ABSTRACT
Introduction: Orthopaedic oncology researchers face
several obstacles in the design and execution of
randomised controlled trials, including finite fiscal
resources to support the rising costs of clinical research
and insufficient patient volume at individual sites. As a
result, high-quality research to guide clinical practice has
lagged behind other surgical subspecialties. A focused
approach is imperative to design a research programme
that is economical, streamlined and addresses clinically
relevant endpoints. The primary objective of this study
will be to use a consensus-based approach to identify
research priorities for international clinical trials in
orthopaedic oncology.
Methods and analysis:We will conduct a 3-phase
modified Delphi method consisting of 2 sequential
rounds of anonymous web-based questionnaires
(phases I and II), and an in-person consensus meeting
(phase III). Participants will suggest research questions
that they believe are of particular importance to the field
(phase I), and individually rate each proposed question
on 5 criteria (phase II). Research questions that meet
predetermined consensus thresholds will be brought
forward to the consensus meeting (phase III) for
discussion by an expert panel. Following these
discussions, the expert panel will be asked to assign
scores for each research question, and research
questions meeting predetermined criteria will be brought
forward for final ranking. The expert panel will then be
asked to rank the top 3 research questions, and these 3
research questions will be distributed to the initial group
of participants for validation.
Ethics and dissemination: An ethics application is
currently under review with the Hamilton Integrated
Research Ethics Board in Hamilton, Ontario, Canada. The
results of this initiative will be disseminated through
peer-reviewed publications and conference presentations.
INTRODUCTION
Barriers to conducting randomised controlled
trials in orthopaedic oncology
Finite resources
Collaborative multicentre randomised con-
trolled trials (RCTs) are considered the gold
standard for the reliable evaluation of
therapeutic interventions. However, large
RCTs have become prohibitively expensive
and increasingly complex, due, in part, to
extensive regulations governing their conduct
and finite fiscal resources.1 Surprisingly, most
federal funding agencies typically spend only
a small proportion of their budgets on RCTs.
For example, the Canadian Institutes of
Health Research allocates <5%, and the
National Institutes of Health allocates <10%.2
Rigorous regulatory requirements, multicen-
tre ethics approvals and institutional contracts
further complicate the research process.3
A trial will succeed only if it can recruit the
required sample size during a predetermined
time period. Large trials require substantial
resources to overcome these challenges and
accomplish their recruitment goals.
Insufficient volume of rare cancers at individual
centres
Sarcomas are rare forms of cancer and repre-
sent <1% of all malignancies. Bone sarcomas
affect just four to five people per million
Strengths and limitations of this study
▪ The primary objective of this study will be to
identify research priorities for international clin-
ical trials in orthopaedic oncology.
▪ The Delphi method has been used extensively in
various fields of healthcare programme planning
and research priority development, but this
protocol represents the first application in the
orthopaedic oncology field.
▪ The anonymity of the Delphi method will minim-
ise domination by individual participants and
eliminate group pressures for conformity.
▪ We will include participants and stakeholders
from varying healthcare systems, organisations
and career stages.
▪ Purposive sampling will lead to the inclusion of par-
ticipants interested in collaborative research, who
may differ from those who decline participation.
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persons each year.4 Insufficient numbers at individual
clinical sites have historically challenged clinical studies
of sarcoma patients. Therefore, multicentre collabor-
ation is imperative to achieve statistical power in order to
draw valid conclusions.5 As a result, the orthopaedic
oncology community continues to face significant knowl-
edge gaps in the surgical management of sarcoma
patients, and many critical questions remain.
Rationale
Lack of evidence from randomised controlled trials
We previously conducted a systematic review to evaluate
the quality of evidence available to guide the surgical
management of lower extremity bone tumours.5 We
identified a complete absence of collaborative multicen-
tre RCTs in orthopaedic oncology, and found that retro-
spective observational studies remain the dominant
source of knowledge. Our results highlight the lack of
prospective collaborative research in this field and a dire
need for innovation and focused effort on
collaboration.6
A paradigm shift in the landscape of musculoskeletal
oncology research
Orthopaedic oncologists have, for decades, discussed
the need for multicentre RCTs, but few centres have the
expertise and logistic support required to coordinate
this type of research. The Prophylactic Antibiotic
Regimens In Tumor surgerY (PARITY) trial
(NCT01479283) is the first-ever multicentre surgical
RCT in orthopaedic oncology, and it represents the first
step in a paradigm shift toward evidence-based patient
care in sarcoma surgery.7 The PARITY trial has the
potential to significantly impact clinical practice well
beyond its primary research objective because it is
leading to the development of an international network
of committed collaborators.8 Properly leveraged, this
promising collaborative group could facilitate additional
high-quality RCTs in the field.
Unmet needs in musculoskeletal oncology
We completed a qualitative study to explore and identify
perceived facilitators and barriers to multicentre collab-
oration in the field. According to our focus group of 13
orthopaedic surgeons from seven countries, we deter-
mined that collaborators were enthusiastic to conduct
further research, provided that the research questions
are clinically important and feasible. We further identi-
fied shared attitudes valuing leadership, expertise, logis-
tical support and centralised infrastructure. This study
confirmed that further investigation into the unmet
needs in orthopaedic oncology research is warranted,
and supports our current protocol as the next logical
step in the development of key strategic research prior-
ities in the field.
Aims
Our primary objective will be to identify research prior-
ities for international clinical trials in orthopaedic oncol-
ogy. We will decide on three potential research questions
that are clinically important and feasible. Our secondary
objectives will be to address critical issues in sarcoma
surgery research, understand the current state of evi-
dence in order to inform study design, facilitate innov-
ation and collaboration among stakeholders, explore
possible funding mechanisms available to support our
research and strategise how to engage relevant patient-
advocacy groups for their input to develop and dissemin-
ate these strategic priorities.
METHODS AND DESIGN
Our planning initiative will employ a three-step modified
Delphi method.9 The process will consist of a qualitative
Figure 1 Planning initiative conduct procedure.
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assessment (phase I), a ranking evaluation (phase II)
and a consensus meeting (phase III) (see figure 1).
The Delphi method is a consensus-based technique
that provides a systematic method of collecting and
aggregating informed judgments from a group of
experts via multiple iterations. Controlled feedback
from sequential rounds encourages participants to
reassess, alter and/or develop opinions. The Delphi
method maximises the benefits of using an expert
panel while minimising potential disadvantages by
implementing anonymity.10 This method has been
used extensively for programme planning and the
development of research priorities in various areas of
medicine, but this protocol represents the first appli-
cation in orthopaedic oncology.11–15
Planning committee
We have formed a Planning Committee comprised of
two orthopaedic oncologists, an orthopaedic Research
Program Manager, the PARITY Project Manager, and a
Health Research Methodology expert to oversee the
design, execution and analysis of all phases of this study.
Research methods were established in face-to-face meet-
ings and email correspondence. Agreement was reached
regarding participant selection, consensus thresholds,
survey format and question structure, and analysis pro-
cesses, according to the proposed quality indicators for a
Delphi study.16
Participant selection
We will invite ∼200 clinician-scientists who are inter-
ested, or are actively participating in the PARITY trial,
Musculoskeletal Tumor Society (MSTS) members,
Connective Tissue Oncology Society (CTOS) members,
International Society of Limb Salvage (ISOLS)
members, and Orthopaedic Research and Education
Foundation (OREF) partners to participate. We expect
to include participants from North and South America,
Europe, Asia, Africa and Australia, and we expect sub-
stantial variation in prior research experience, clinical
focus and career stage.
Delphi procedure
Phase I—qualitative assessment
The first phase will use a web-based, open-ended ques-
tionnaire (see online supplementary appendix 1) asking
participants to identify up to three research questions
that they believe are of particular importance to the
field of orthopaedic oncology. Participants will be
invited to complete the questionnaire via email.
Participants’ responses will not be guided by accompany-
ing facilitators or literature reviews. Instead, they will
be asked to review the literature and consult with collea-
gues as they see fit prior to proposing their ideas.
Participants will also be asked to provide some de-
mographic information and to declare any potential
financial or intellectual conflicts of interest. The ques-
tionnaires will remain online for up to 4 weeks, and
reminder emails will be sent out approximately every
7 days after the initial invitation.
Once all the questionnaires have been received, we
will compile the responses and review the proposals to
generate a list of candidate research questions that will
progress to phase II. Responses from phase I will be ini-
tially reviewed by a Planning Committee member who is
familiar with orthopaedic oncology. Similar ideas will be
clustered together into emerging research questions;
duplicate responses and those deemed not applicable
will then be removed. This review will be repeated inde-
pendently by a Health Research Methodology expert.
The two reviewers will then meet to discuss any differ-
ences produced from these independent analyses.
Phase II—ranking evaluation
During the second phase, participants will be emailed a
questionnaire (see online supplementary appendix 2)
asking them to rank each candidate research question
individually on a 5-point Likert scale (see table 1) for
five criteria: scientific merit, significance, innovation,
relevance and feasibility. Participants will also be asked
to further clarify or add to research questions, and
comment on their rankings.
Once all the questionnaires have been received, we
will compile the rankings for each research question and
any additional responses. Using predetermined consen-
sus thresholds (see Table 2), we will decide which
research questions will be brought forward to the con-
sensus meeting for review. Research questions that meet
the inclusion or non-consensus thresholds will progress
to phase III for review. Research questions that meet the
exclusion consensus threshold will not be brought
forward for review. If none of the research questions
meet the inclusion or non-consensus thresholds, the
thresholds will be lowered until a critical mass of
Table 2 Phase II consensus thresholds
Consensus thresholds
Inclusion >75% of respondents provide a positive
result (four or five) on the Likert scale for
all criteria.
Exclusion >75% of respondents provide a negative
result (one or two) on the Likert scale for
all criteria.
Non-consensus When the proposed priority research
question has met neither the inclusion
nor exclusion consensus thresholds.
Table 1 Phase II 5-point Likert scale
1 2 3 4 5
Strongly
disagree
Disagree Neither
agree nor
disagree
Agree Strongly
agree
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research questions are able to be brought forward to the
next phase. We consider a priori that a critical mass of
10 priority research questions will suffice. However,
Delphi processes tend to be flexible and, therefore, it is
more likely that there will be a large number of ques-
tions brought forward for discussion.17 If this is the case,
we will rank the questions in tiers and give priority to
discussion of the highest ranking tier.
Phase III—in-person expert panel consensus meeting
We will hold an in-person expert panel consensus at the
MSTS 2016 Annual Meeting. An experienced facilitator
will moderate the meeting. We will invite all participants
from phases I and II to participate, as well as representa-
tives from patient advocacy groups, MSTS, CTOS, ISOLS
and OREF. Should too many individuals express their
interest in participating on the expert panel, we will
select a diverse and balanced group comprised of 20
individuals, with at least one individual from each of the
geographical, stakeholder and career stage groups. All
individuals involved in phase III will be asked to expli-
citly identify any known biases prior to their participa-
tion in the consensus meeting (which will be
documented using Conflict of Interest disclosure
statements), and may be asked not to participate in
certain parts of the discussion.18
We will implement Powercom anonymous electronic
audience response devices to enable anonymous scoring
throughout the meeting. A semistructured agenda will be
provided to minimise time constraints, and to ensure that
all individual participants are allowed a period of uninter-
rupted time to voice their opinions for each topic dis-
cussed (see figure 2). Each proposed research question
will be individually discussed by the expert panel, thereby
providing an opportunity for members to reconsider
their initial ratings in light of other members’ views.
When differences in the ratings from phase II appear to
have resulted due to ambiguity in the wording of the
research question, the members will agree to a revised
wording. Following these discussions, the members will
be asked to anonymously assign a score from 1 to 9 for
each research question (see table 3).
Once the scores have been compiled, those meeting
one of the following predetermined criteria will be
brought forward for final ranking:
▸ 100% of respondents scored the research question as
either a seven, eight or nine; or
▸ At least 10% of respondents scored the research ques-
tion as a nine.
Figure 2 In-person expert panel consensus meeting agenda.
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If none of the research questions meet these criteria,
the top 10 scoring research questions will be brought
forward for final ranking.
These highest ranked research questions will once
again be discussed by the expert panel. The members
will then be asked to rank their top three research ques-
tions. The three research questions with the highest
mean scores (see table 4) will be validated by the initial
group and recommended in the final report as priority
questions for future research in the field.
We will also use the phase III consensus meeting to
discuss critical issues in sarcoma surgery research, under-
stand the current state of evidence in order to inform
study design, facilitate innovation and collaboration
among stakeholders, explore possible funding mechan-
isms available to support our research, and strategise
how to engage relevant patient-advocacy groups for their
input to develop and disseminate these strategic
priorities.
Statistical analysis
We will report discrete variables as counts or propor-
tions, normally distributed continuous variables as
means with SDs , and skewed continuous variables as
medians with IQRs. We will compare results across differ-
ent stakeholder groups, regions and career stages using
χ2 tests or ANOVA with individual pair-wise comparisons.
Rank correlation will be determined using the
Spearman coefficient. All tests of significance will be
two-tailed, and p values of <0.05 will be considered
significant.
Ethics
An ethics application is currently under review with the
Hamilton Integrated Research Ethics Board in
Hamilton, Ontario, Canada. Potential participants will
be informed that responding to the questionnaires
implies consent to participate in the initiative, and
having their deidentified responses included in future
iterations and any analyses. The consensus meeting
facilitator will also clearly explain the purpose of the ini-
tiative to the expert panel participants and will obtain
written informed consent prior to commencement of
the meeting. All anonymised data will be kept on a pass-
word protected computer on a secure network and in a
locked office, in accordance with local guidelines. The
data will only be accessible to the Planning Committee,
and will be destroyed after 10 years, as per local
guidelines.
DISCUSSION
The application of consensus methods is critical where
unanimity of opinion does not exist due to a lack of or
conflicting evidence on a given issue. These methods
provide a means of synthesising the valuable insights of
experts to either assess the extent of agreement (consen-
sus measurement) or to resolve disagreement (consen-
sus development).19 Accordingly, consensus methods are
being increasingly employed to enhance the effective
development of research priorities in medicine.11–13 15
Two consensus methods commonly used in medical
research are the Nominal Group Technique (NGT) and
the Delphi method.19
The NGT uses a structured meeting to facilitate the
discussion and the collection of data for a particular
issue.18 The direct interaction during the meeting
allows participants to clarify and justify their points of
view, which may help the group make more informed
decisions.19 It is, however, often impractical to secure
the participation of all key knowledgeable individuals.19
As previously described, the classical Delphi method is
an iterative process used to solicit and distil the judg-
ments of experts using a series of questionnaires alter-
nated with feedback.10 This method allows for
information to be obtained from a greater number of
individuals and does not impose geographical con-
straints.10 However, a lack of face-to-face interaction pre-
vents participants from exploring reasons for
disagreements, thereby limiting the chance for opinions
to be modified in response to such discussions.19 A
hybrid of these two methods, the modified Delphi
method, maximises the benefits of both consensus
methods through the initial collection of information
via questionnaires (consensus measurement) followed
by a structured in-person meeting (consensus
development).
The validity of several consensus methods has been
questioned due to manipulation of the processes by
organisers, domination of discussions by certain partici-
pants, and group pressure for conformity.19 To avoid
imposing our views on participants and thereby introdu-
cing information error into the evaluation, we will begin
Table 3 Phase III scoring scale
1 2 3 4 5 6 7 8 9
Should not be
studied
Lowest
priority
Very low
priority
Low
priority
Medium
priority
Slightly high
priority
Moderately high
priority
High
priority
Highest
priority
Table 4 Phase III final ranking scoring system
Rank 1st 2nd 3rd
Points 3 2 1
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with an open-ended questionnaire.9 Furthermore, in our
modified Delphi approach, all responses will remain
anonymous, and any discussion will be moderated by an
experienced facilitator. The anonymity of phases I and II
will ensure that all ratings are given the same import-
ance in phase III.9 The discussion of phase III will
provide an equal chance for each expert panel member
to reassess their views through moderated discussion
without compromising the anonymity of the scoring.
These measures should ensure that various response
biases are minimised, and that the final ranking does
not merely reflect the perspectives of any single individ-
ual. Moreover, some individuals, especially those with
minority views, may be more likely to drop out of a con-
sensus process; this attrition can lead to overestimation
of the final degree of consensus.
The purposive sampling employed by the Delphi
method may lead to having only participants who are inter-
ested in collaborative research in the field.20 However, con-
sidering that our objective is to determine priority research
questions in orthopaedic oncology in order to drive future
multicentre prospective research, this bias is actually favour-
able, as participants will likely provide insightful ideas.
Nevertheless, by including participants from different
healthcare systems, organisations and career stages, we still
plan on assembling a relatively diverse panel.
DISSEMINATION PLAN
We expect that the results of this initiative will be pub-
lished in a high-impact peer-reviewed journal, which will
lend credibility to future grant applications and provide
an opportunity for participants to publish as a collabora-
tive group. Furthermore, the findings of this initiative
will also be disseminated to regional, national and inter-
national audiences through presentations at relevant
research conferences. Finally, the results of this study
will be brought forward to initiate the next phase of col-
laborative research in orthopaedic oncology. Such col-
laborative research will be imperative to advance surgical
care in patient with sarcoma.
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